{"id":580645,"date":"2021-12-30T17:10:01","date_gmt":"2021-12-30T17:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=580645"},"modified":"2021-12-30T17:10:01","modified_gmt":"2021-12-30T17:10:01","slug":"hemophilia-b-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-2030-delveinsight-key-companies-pfizer-novo-nordisk-bioverativ-csl-behring-sanofi-uniqure-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-b-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-2030-delveinsight-key-companies-pfizer-novo-nordisk-bioverativ-csl-behring-sanofi-uniqure-and-others_580645.html","title":{"rendered":"Hemophilia B Market to Grow at a Substantial Growth Rate During the Forecast Period 2030 – DelveInsight | Key Companies – Pfizer, Novo Nordisk, Bioverativ, CSL Behring, Sanofi, UniQure, and Others"},"content":{"rendered":"
\n
\"Hemophilia<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Hemophilia B Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Hemophilia B market<\/strong> report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n

\"Hemophilia<\/p>\n

Hemophilia B: An Overview<\/strong><\/p>\n

According to the Centers for Disease Control and Prevention, Hemophilia B is a genetic disorder caused by missing or defective Factor IX clotting protein. With the lack of this, the blood cannot clot properly to control bleeding like hemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.<\/em><\/p>\n

The main signs and symptoms of hemophilia are excessive bleeding and easy bruising. The child may suffer from recurrent nose bleeds, blood loss from small cuts, long-term bleeding in the mouth from bites, or after removal of a tooth, on-and-off bleeding from a cut or injury, bleeding within the skin or muscle, and soft tissue that causes a build-up of blood in the area. The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity.<\/em><\/p>\n

Hemophilia B Market Key Facts<\/strong><\/p>\n